Transdermal system for varenicline
AssigneePfizer Inc.
InventorsBarbara Alice Johnson, Carl Bernard Ziegler
Life of this patent
Estimating the term…
Abstract
The invention provides transdermal compositions comprising varenicline or its pharmaceutically acceptable salt or prodrug form.
Claims16
A transdermal composition comprising varenicline or its pharmaceutically acceptable salt or prodrug form.
A method for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a subject, comprising transdermal administration to a subject an amount of varenicline that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use.
A method of making a pressure sensitive adhesive matrix patch for transdermal delivery of varenicline by the steps consisting of:
- (a) dissolving an effective amount of varenicline in an aqueous dispersion, comprising a water phase, a hydrophobic pressure sensitive adhesive and optionally a permeation enhancer, to form a mixture;
- (b) film casting the mixture and evaporating the water phase to obtain a hydrophobic pressure sensitive adhesive matrix film having first and second surfaces, the varenicline being fully dissolved therein;
- and,
- (c) laminating a release liner to the first surface of the matrix film and a substantially drug-impermeable backing layer to the second surface, thereby providing a pressure-sensitive adhesive matrix patch for transdermal delivery of varenicline.
A sprayable liquid for preparation of a transdermal composition of varenicline, or a pharmaceutically acceptable salt thereof. comprising phospholipidic gel-forming agent, ethanol, varenicline, phosphate buffer, and water.
Dependencies are inferred from the claim text.